# US 2023/0057150 A1 · HUMAN IgG Fc DOMAIN VARIANTS WITH IMPROVED EFFECTOR FUNCTION

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0057150 A1
- Document ID: US20230057150A1
- Status: Published application
- Kind: A1
- Application number: 17/699,716
- Filed: 2022-03-21
- Published: 2023-02-23
- Earliest claimed: 2017-12-19
- Assignees: The Rockefeller University
- Applicants: The Rockefeller University
- Inventors: Jeffrey V. Ravetch; Stylianos Bournazos
- Web page: https://patentgrep.com/patent/US20230057150A1

## CPC

- C07K 16/30: from tumour cells
- C07K 16/00: Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K 16/2887: {against CD20}
- C07K 16/462: {Igs containing a variable region (Fv) from one specie and a constant region (Fc) from another}
- C12N 15/85: for animal cells
- G01N 33/563: involving antibody fragments
- A61K 2039/505: {comprising antibodies}
- A61P 35/00: Antineoplastic agents
- C07K 2317/21: from primates, e.g. man
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C07K 2317/52: Constant or Fc region; Isotype
- C07K 2317/732: Antibody-dependent cellular cytotoxicity [ADCC]
- C07K 2317/734: Complement-dependent cytotoxicity [CDC]
- C07K 2317/94: Stability, e.g. half-life, pH, temperature or enzyme-resistance
- C07K 2319/035: containing a signal for targeting to the external surface of a cell, e.g. to the outer membrane of Gram negative bacteria, GPI- anchored eukaryote proteins
- C07K 2319/33: fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
- C07K 2319/35: containing a fusion for enhanced stability/folding during expression, e.g. fusions with chaperones or thioredoxin
- C12N 2015/8518: {expressing industrially exogenous proteins, e.g. for pharmaceutical use, human insulin, blood factors, immunoglobulins, pseudoparticles}
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to human IgG Fc domain variants with improved effector function and uses thereof.

## Claims

### Claim 1

A polypeptide comprising an Fc variant of a human IgG I Fc polypeptide, wherein the Fc variant comprises an Alanine (A) at position 236, a Leucine (L) at position 330, and a Glutamic acid (E) at position 332, and a Serine (S) at position 239, a Leucine (L) at position 428, and a Serine (S) at position 434, wherein the numbering is according to the EU index in Kabat, and wherein an antibody having the Fc variant has a half life comparable to the antibody having the wild-type IgG1 Fc sequence of SEQ ID NO: 1.

### Claim 2

(canceled)

### Claim 3

(canceled)

### Claim 4 (depends on 1)

The polypeptide of claim 1, wherein the Fc variant comprises the sequence of SEQ ID NO: 3.

### Claim 5 (depends on 1)

An antibody comprising the polypeptide of claim 1.

### Claim 6 (depends on 5)

The antibody of claim 5, wherein the antibody has specificity for a target molecule.

### Claim 7 (depends on 6)

The antibody of claim 6, wherein the target molecule is selected from the group consisting of a cytokine, a soluble factor, a molecule expressed on a pathogen, a molecule expressed on cells, and a molecule expressed on cancer cells.

### Claim 8 (depends on 5)

The antibody of claim 5, wherein the antibody is selected from the group consisting of a chimeric antibody, a humanized antibody, and a human antibody.

### Claim 9 (depends on 5)

The antibody of claim 5, wherein the antibody has one or more of the following features: (1) a higher binding affinity to hFcyRIIA, hFcyRIIIA, hFcRn, or/and hFcyRIIIB as compared to an antibody having the sequence of SEQ ID NO: 1, (2) a longer serum half-life as compared to an antibody having the sequence of SEQ ID NO: 4, and (3) identical or better half-life as compared to an antibody having the sequence of SEQ ID NO: 1.

### Claim 10 (depends on 5)

A nucleic acid comprising a sequence encoding the antibody of claim 5.

### Claim 11 (depends on 10)

An expression vector comprising the nucleic acid of claim 10.

### Claim 12 (depends on 10)

A host cell comprising the nucleic acid of claim 10.

### Claim 13 (depends on 12)

A method of producing a polypeptide or an antibody, comprising culturing the host cell of claim 12 in a medium under conditions permitting expression of a polypeptide or antibody encoded by the nucleic acid, and purifying the polypeptide or antibody from the cultured cell or the medium of the cell.

### Claim 14 (depends on 5)

A pharmaceutical formulation comprising (i) the antibody of claim 5, and (ii) a pharmaceutically acceptable carrier.

### Claim 15 (depends on 5)

A method of treating an inflammatory disorder, comprising administering to a subject in need thereof a therapeutically effective amount of the antibody of claim 5.

### Claim 16 (depends on 5)

A method of treating a neoplastic disorder, comprising administering to a subject in need thereof a therapeutically effective amount of the antibody of claim 5.

### Claim 17 (depends on 5)

A method of treating an infectious disease, comprising administering to a subject in need thereof a therapeutically effective amount of the antibody of claim 5.

### Claim 18

(canceled)

### Claim 19

(canceled)

### Claim 20

(canceled)
